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Abstract
Background: Valproic acid (VPA), a commonly used mood stabilizer that promotes neuronal
differentiation, regulates multiple signaling pathways involving extracellular signal-regulated kinase
(ERK) and glycogen synthase kinase3β (GSK3β). However, the mechanism by which VPA promotes
differentiation is not understood.
Results: We report here that 1 mM VPA simultaneously induces differentiation and reduces
proliferation of basic fibroblast growth factor (bFGF)-treated embryonic day 14 (E14) rat cerebral
cortex neural progenitor cells (NPCs). The effects of VPA on the regulation of differentiation and
inhibition of proliferation occur via the ERK-p21Cip/WAF1 pathway. These effects, however, are not
mediated by the pathway involving the epidermal growth factor receptor (EGFR) but via the
pathway which stabilizes Ras through β-catenin signaling. Stimulation of differentiation and
inhibition of proliferation in NPCs by VPA occur independently and the β-catenin-Ras-ERK-p21Cip/
WAF1 pathway is involved in both processes. The independent regulation of differentiation and
proliferation in NPCs by VPA was also demonstrated in vivo in the cerebral cortex of developing
rat embryos.
Conclusion: We propose that this mechanism of VPA action may contribute to an explanation of
its anti-tumor and neuroprotective effects, as well as elucidate its role in the independent
regulation of differentiation and inhibition of proliferation in the cerebral cortex of developing rat
embryos.
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Background
Valproic acid (VPA; 2-propyl-pentanoic acid) has been
used for mood stabilization and the treatment of epilepsy
for several decades [1]. VPA also exhibits potent in vitro
and in vivo anti-tumor effects in leukemic cells, neuroblas-
tomas, and gliomas [2-7]. VPA is a histone deacetylase
(HDAC) inhibitor and plays a role in modifying chroma-
tin structure and gene expression [8,9]. VPA has also been
found to affect various signaling systems, including the
extracellular signal-regulated kinase (ERK), protein kinase
C (PKC), and the Wnt/β-catenin pathways [3,10,11]. VPA
alters the Wnt/β-catenin signaling by directly or indirectly
[12,13] inhibiting the activity of glycogen synthase kinase
3β (GSK3β).
VPA has been reported to regulate the differentiation and
proliferation of various cells, including mesenchymal and
hematopoietic stem cells, neuroblastoma cells, primary
neurons, and neural progenitor cells (NPCs) [8,14-17].
VPA can also reduce the proliferation of neuroblastoma
cells by induction of the cell cycle regulator p21Cip/WAF1
[5,6], which is also known to be involved in the VPA-
induced differentiation of hematopoietic cells [18]. How-
ever, the mechanism by which VPA regulates differentia-
tion and proliferation is not understood.
We report here that 1 mM VPA induces differentiation and
inhibits proliferation of NPCs by overcoming the effect of
basic fibroblast growth factor (bFGF), a factor which
inhibits the differentiation of NPCs [19,20]. VPA-induced
activation of the ERK- p21Cip/WAF1 pathway did not occur
via the common pathway involving epidermal growth fac-
tor receptor (EGFR), an upstream component of the ERK
pathway, as indicated by significant reduction in the level
of EGFR in the presence of VPA. The level of Ras protein,
another upstream component of the ERK pathway, was
significantly increased by VPA treatment. This observation
led us to conclude that VPA-induced ERK pathway activa-
tion occurs via an increase in the stability of Ras, mediated
by Wnt/β-catenin signaling [21,22]. We also found that
the common Ras-ERK-p21Cip//WAF1 pathway is involved in
generating the mutually exclusive phenotypes of differen-
tiation and proliferation in NPCs and in brain tissue of
the cerebral cortex of developing embryos.
Results
VPA overcomes the effects of bFGF on differentiation and 
proliferation in multipotent NPCs
Basic fibroblast growth factor (bFGF) is necessary for the
maintenance of multipotency in neural progenitor cells
[20] and is involved in the regulation of differentiation
and growth in neuronal cells [23-25]. In agreement with
earlier reports, we found that NPCs isolated from the cer-
ebral cortex of E14 rat embryos underwent morphologic
differentiation when grown in N2 medium alone (Figure
1A, upper left panel). The NPCs retain the capacity for
self-renewal, as shown by their ability to form neuro-
spheres, by a process of dissociation and reformation, for
several passages in culture (see Additional file 1). The
NPCs also retain the property of multipotency, as shown
by their capacity to differentiate into primary neurons, oli-
godendrocytes, and astrocytes (see Additional file 1). The
NPCs maintained an undifferentiated morphology when
grown in the presence of 10 ng/ml bFGF (Figure 1A, lower
left panel). The differentiation-suppressing and prolifera-
tive effects of bFGF were partly overcome by treatment
with 1 mM VPA (Figure 1A, lower right panel). Cells
treated with VPA and bFGF also exhibited more pro-
nounced neurite outgrowth compared to cells treated with
bFGF alone. The effect of VPA on morphologic differenti-
ation in the presence of bFGF was dose-dependent (see
Additional file 2). No evidence of cell toxicity was
detected in the presence of 1 mM VPA and this concentra-
tion was used in the remaining experiments. Not only do
NPCs grown in the presence of bFGF for 48 h remain mor-
phologically undifferentiated, but the cells also had a high
proliferation rate, as indicated by a five-fold increase in
total cell number compared to untreated cultures (Figure
1B). In contrast, co-treatment with 1 mM VPA for 48 h
reduced cell number by 60% compared to cells treated
with bFGF alone (Figure 1B). VPA did not alter cell
number in cultures grown in the absence of bFGF. There-
fore, VPA induced both differentiation and inhibition of
proliferation in NPCs by overcoming the anti-differentia-
tion and pro-growth effects of bFGF.
VPA induces both p21Cip/WAF1 and Tuj1 via the Raf-MEK-
ERK cascade in NPCs grown in the presence of bFGF
The ERK pathway is involved in both positive and nega-
tive regulations of cell growth depending upon the inten-
sity and duration of the signals [26-28] and VPA can
activate the ERK pathway in primary neurons in culture
[29,30]. To investigate the potential involvement of the
ERK pathway in VPA-induced differentiation and growth
inhibition in bFGF-treated NPCs, the activation status of
Raf-1, MEK, and ERK was examined. Immunoblot analy-
sis revealed that VPA treatment elicited an increase in ERK
activity, as indicated by an increase in the levels of phos-
phorylated ERK (p-ERK), in NPCs grown in bFGF. The lev-
els of phosphorylated MEK (p-MEK) and Raf-1 (p-Raf-1)
were also increased in NPCs in which differentiation had
been induced and proliferation had been inhibited by
treatment with VPA (Figure 2A). Induction of the cell cycle
regulator p21Cip/WAF1 is an important indicator of ERK
pathway-induced inhibition of proliferation [28,31]. In
accordance with its anti-proliferative effect, VPA elicited
an increase in p21Cip/WAF1 levels in NPCs grown in the
presence of bFGF (Figure 2A). Immunocytochemical anal-BMC Cell Biology 2008, 9:66 http://www.biomedcentral.com/1471-2121/9/66
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ysis of NPCs revealed that the induction of p21Cip/WAF1 by
VPA was accompanied by accumulation of p21Cip/WAF1 in
the cell nuclei (Figure 2B; left panel). The number of cells
containing positive nuclear staining of p21Cip/WAF1
increased from 5% to 87.5% in response to VPA treatment
(Figure 2B, right panel). In contrast, the percentage of pro-
liferating cells, which incorporated BrdU into their nuclei,
was reduced from 73% to 15% in response to treatment
with 1 mM VPA (Figure 2C). Immunoblot analysis
revealed that the level of Tuj1, a specific marker of imma-
ture neurons, increased in NPCs grown in the presence of
VPA and bFGF (Figure 2A). Immunocytochemical analy-
sis confirmed these findings and also showed marked,
enhanced neurite outgrowth in cells showing significantly
increased levels of Tuj1 (Figure 2D).
To ascertain whether the ERK pathway mediates p21Cip/
WAF1 induction and neuronal differentiation in response
to VPA, we measured the effect of inhibition of the Ras-
ERK pathway on the induction of p21Cip/WAF1 and Tuj1 by
VPA. Induction of p21Cip/WAF1 by VPA was significantly
reduced when ERK activation was inhibited by the MEK
inhibitor PD98059 (Figure 2E). Induction of Tuj1 by VPA
was also reduced by PD98059. The VPA-induced activa-
tion of the ERK pathway in the inhibition of growth of
NPCs in the presence of bFGF was confirmed by the obser-
vation of re-increase of cell numbers by treatment with
PD98059 in the presence of VPA (Figure 2F). We did not
observe any growth-stimulatory effect of PD98059 when
NPCs were grown in the absence of bFGF; rather, cell
number was somewhat reduced by PD98059 treatment
(see Additional file 3). In summary, VPA induces differen-
tiation and inhibition of proliferation via the Ras→ME-
K→ERK pathway in NPCs grown in the presence of bFGF.
p21Cip/WAF1 mediates VPA-induced differentiation and 
inhibition of proliferation in NPCs grown in the presence 
of bFGF
VPA-induced ERK activation and p21Cip/WAF1 induction
were not observed in the Tuj1-induced, differentiated
NPCs grown in the absence of bFGF, as shown by both
biochemical (Figure 3A) and immunocytochemical (Fig-
ure 3B) analyses. In these cultures, the number of BrdU-
positive cells was relatively low and was not changed by
VPA treatment (see Additional file 4). To determine the
role of p21Cip/WAF1 in VPA-induced differentiation and
inhibition of proliferation, we analyzed the effect of
p21Cip/WAF1 siRNA. Stimulation of neuronal differentia-
tion and inhibition of proliferation in NPCs by VPA treat-
ment were diminished by p21Cip/WAF1 siRNA as shown by
Effect of VPA on morphology and proliferation of NPCs Figure 1
Effect of VPA on morphology and proliferation of NPCs. NPCs were treated with 1 mM VPA for 48 h in the presence 
or absence of 10 ng/ml bFGF. (A) Micrographs were taken at a magnification of 200×. (B) Cells were harvested and then 
counted using a hemocytometer. In three independent experiments, cells within the 230-μm square were counted and 
expressed as percent of the total number of cells in bFGF-treated cultures. Data represent mean ± SD of three separate 
experiments. P*** < 0.001 by one-way ANOVA followed by Newman-Keuls test.BMC Cell Biology 2008, 9:66 http://www.biomedcentral.com/1471-2121/9/66
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both biochemical (Figure 3C) and immunocytochemical
(Figure 3D) analyses. Inhibition of proliferation, one of
the effects of VPA on NPCs as assessed by BrdU incorpo-
ration, was also released after treatment with p21Cip/WAF1
siRNA (Figure 3D; quantitative data are shown in Addi-
tional file 5). The majority of cells exhibiting nuclear accu-
mulation of p21Cip/WAF1 after VPA treatment were also
BrdU-negative, underscoring the important anti-prolifera-
tive role of p21Cip/WAF1 (Figure 3E).
VPA activates the ERK-p21Cip/WAF1 pathway and induces 
differentiation and inhibition of proliferation via  -catenin-
mediated accumulation of Ras in NPCs grown in the 
presence of bFGF
The epidermal growth factor receptor (EGFR) most often
mediates activation of the ERK pathway by extracellular
stimuli [32]. Although, in this study, the ERK pathway was
activated by VPA, we were surprised to find that EGFR lev-
els were reduced by VPA treatment in NPCs grown in the
Effect of VPA on activities of ERK pathway components and on expression of p21Cip/WAF1 and Tuj1 Figure 2
Effect of VPA on activities of ERK pathway components and on expression of p21Cip/WAF1 and Tuj1. NPCs grown 
in 10 ng/ml bFGF were treated with 1 mM VPA for 48 h. (A) Whole-cell lysates were subjected to immunoblotting for analysis 
of the presence of p-ERK, p-MEK, p-Raf-1, p21Cip/WAF1, Tuj1, or β-actin. Alternatively, NPCs were processed for immunofluo-
rescent labeling of (B) p21Cip/WAF1 (green), (C) BrdU (red), or (D) Tuj1 (green). Nuclei were counterstained with DAPI (blue). 
All images are 200× magnifications. The percentage of cells that exhibited nuclear p21Cip/WAF1 in the presence and absence of 
VPA is presented, along with the percentage of BrdU-positive and Tuj1-positive cells. Error bars indicate the standard devia-
tions of three independent experiments. Data represent mean ± SD of three separate experiments. P*** < 0.001, P** < 0.01 by 
Student's t-test. (B-C). Effects of inhibition of ERK pathway on p21Cip/WAF1 and Tuj1 induction by VPA. (E) NPCs grown in the 
presence of 10 ng/ml bFGF were treated with different combinations of 20 μM PD98059 and 1 mM VPA. (F) NPCs grown in 
the presence of 10 ng/ml bFGF were treated as in (E). In three independent experiments, cells within the 230-μm square were 
counted and expressed as a percentage of the total number of cells. Values represent the mean ± SD of three separate exper-
iments. P** < 0.01, P*** < 0.001 by one-way ANOVA followed by Newman-Keuls test.BMC Cell Biology 2008, 9:66 http://www.biomedcentral.com/1471-2121/9/66
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presence of bFGF (Figure 4A). The VPA-induced decrease
in EGFR levels was convincingly seen in the time course of
VPA treatment after treatment with 1 mM VPA (Figure
4B). VPA regulates the Wnt/β-catenin pathway by direct
binding and inhibition of GSK3β [12,13]. In this study,
we also observed an increase in the level of phospho-Ser-
9-GSK3 (p-GSK3β), an inactive form of GSK3β [14], and
β-catenin following VPA treatment (Figure 4A). It is also
known that Ras protein levels are subject to regulation by
the Wnt/β-catenin pathway in several cell types, including
primary hepatocytes, and β-catenin has been identified as
a mediator in that process [21,22]. Here, we found that
the level of Ras protein was significantly up-regulated in
NPCs treated with VPA, leading to an increase in p-GSK3β
and its target, β-catenin (Figure 4A). The role of β-catenin
in the regulation of Ras was further indicated by similar
patterns of increase in Ras and β-catenin levels during the
time course of VPA treatment (Figure 4B).
To identify the role of β-catenin in the regulation of the
Ras-ERK-p21Cip/WAF1 pathway and subsequent stimulation
of differentiation and inhibition of proliferation induced
by VPA in NPCs, we measured the effect of overexpression
of β-catenin. Overexpression of β-catenin increased ERK
activity and Ras protein level and induced expression of
p21Cip/WAF1 and Tuj1 (Figure 4C). Cells overexpressing β-
Effects of bFGF and p21Cip/WAF1 siRNA on regulation of the VPA-induced differentiation and inhibition of proliferation in NPCs Figure 3
Effects of bFGF and p21Cip/WAF1 siRNA on regulation of the VPA-induced differentiation and inhibition of prolif-
eration in NPCs (A-B). NPCs were treated with 1 mM VPA for 48 h in the presence or absence of 10 ng/ml bFGF. (C-D) 
NPCs were transfected with 100 nM p21Cip/WAF1 siRNA prior to treatment with 1 mM VPA for 48 h in the presence of 10 ng/
ml bFGF. Whole-cell lysates were subjected to immunoblotting to detect p21Cip/WAF1, Tuj1, or β-actin. Alternatively, cells were 
processed for immunofluorescent labeling to detect the presence of Tuj1 (green), p21Cip/WAF1 (green), or BrdU (red). Nuclei 
were counterstained with DAPI. Images are 400× magnifications. (E) NPCs were treated with 1 mM VPA for 48 h in the pres-
ence of 10 ng/ml bFGF. Cells were processed for immunofluorescent labeling to detect the presence of p21Cip/WAF1 (green) or 
BrdU (red). Nuclei were counterstained with DAPI. Magnification is 1200×.BMC Cell Biology 2008, 9:66 http://www.biomedcentral.com/1471-2121/9/66
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catenin were morphologically differentiated and BrdU-
negative (Figure 4D). Therefore, β-catenin is an important
factor for both differentiation and inhibition of prolifera-
tion in cortical E14 NPCs and those physiological
responses are simultaneously and independently control-
led by β-catenin.
The role of β-catenin in the VPA-induced expression of
Tuj1 and p21Cip/WAF1 in NPCs was further investigated by
measurement of the effects of β-catenin siRNA. We
observed that the VPA-induced increase in Ras was
reduced following β-catenin knockdown (Figure 5A). ERK
activation, and subsequent induction of Tuj1 and p21Cip/
WAF1, was also reduced by β-catenin knockdown (Figure
5A), indicating that β-catenin, at least in part, mediates
the effect of VPA on the activation of the ERK-p21Cip/WAF1-
Tuj1 pathway via stabilization of Ras. VPA-induced reduc-
tion in EGFR levels was not affected by β-catenin knock-
down. The role of β-catenin in VPA-induced
differentiation and inhibition of proliferation was also
examined (Figure 5B and 5C). Immunocytochemical
analysis revealed that β-catenin siRNA significantly
reduced VPA-mediated induction of Tuj1 in NPCs (Figure
5B). In contrast, the number of BrdU-positive cells, which
initially decreased in the presence of VPA, was marginally
increased by VPA treatment following silencing of β-cat-
enin (Figure 5C; quantitative data are shown in Addi-
tional file 6).
VPA independently induces differentiation and inhibition 
of proliferation in NPCs in the developing rat brain
To understand the physiological relevance of the effects of
VPA observed in vitro, we administered VPA to E13.5 rat
embryos and examined the effect on differentiation and
proliferation in the cerebral cortex. In the absence of VPA,
the immunofluorescent labeling patterns of proliferating
cell nuclear antigen (PCNA) and Tuj1 in the cerebral cor-
tex of the developing rat embryo were distinct and non-
Effects of VPA or β-catenin on EGFR, β-catenin, and Ras regulation Figure 4
Effects of VPA or β-catenin on EGFR, β-catenin, and Ras regulation. (A-B) NPCs grown in 10 ng/ml bFGF were 
treated with 1 mM VPA for 48 h or different periods of time. (C-D) NPCs were transfected with pcDNA3.0 or Flag-β-catenin-
pcDNA3.0 and grown in the presence of 10 ng/ml bFGF. (A-C) Whole-cell lysates were then subjected to immunoblotting for 
detection of p-GSK3β (Ser-9), β-catenin, Pan-Ras, p-ERK, p21Cip/WAF1, Tuj1, EGFR, or β-actin. (D) Immunofluorescent labeling 
was performed for Flag or BrdU. Nuclei were counterstained with DAPI.BMC Cell Biology 2008, 9:66 http://www.biomedcentral.com/1471-2121/9/66
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overlapping (Figure 6A and 6B). In control embryos
injected with PBS alone, Tuj1 staining was predominantly
localized to the cortical plate (CP) area, where differenti-
ated neuronal cells reside. However, PCNA staining was
primarily localized to the subventricular zone (SVZ) and
the intermediate zone (IMZ), where neural stem/progeni-
tor cells reside (Figure 6B; left panel). The number of cells
that had differentiated into neurons was significantly
increased by VPA, to the extent that both the area occu-
pied by Tuj1-positive cells and the intensity of the Tuj1
staining were significantly increased in the CP region (Fig-
ure 6B). In contrast, the intensity and number of PCNA-
positive cells were significantly reduced by VPA in the SVZ
and IMZ of the cerebral cortex (Figure 6B); of the cerebral
cortical cells induced to differentiate by VPA treatment,
none were PCNA-positive. Demonstration of differentia-
tion and proliferation in cells of the VPA-treated cerebral
cortex was also carried out in vitro, and similar distinct pat-
terns of Tuj1 and BrdU staining were observed in the VPA-
treated NPCs grown in the presence of bFGF (Figure 6C).
Discussion
In the present study, we found that NPCs undergo neuro-
nal differentiation and inhibition of proliferation follow-
ing treatment with 1 mM of the commonly prescribed
antiepileptic drug VPA [1]. We chose 1 mM VPA because
this concentration is non-toxic to the NPCs in our current
study and to hippocampal neuronal progenitors [2]. The
VPA amount applied to the animals, 200 mg/kg, is identi-
cal to that used to achieve whole-brain levels of 1.0–1.5
mM by chronic application [1].
We investigated the mechanism by which VPA regulates
differentiation and inhibition of proliferation. The role of
VPA in the exclusive in vivo regulation of differentiation
and proliferation of NPCs suggest an application for VPA
in the production of functional neurons for therapeutic
use in patients. Our study also provides a mechanism that
may aid in validating the proposed use of VPA as an anti-
tumor and neuroprotective agent [3,4,33]. VPA induced
both differentiation and inhibition of proliferation in
Effects of β-catenin knockdown on Ras-ERK pathway activation and VPA-induced differentiation and inhibition of proliferation Figure 5
Effects of β-catenin knockdown on Ras-ERK pathway activation and VPA-induced differentiation and inhibition 
of proliferation. NPCs were transfected with 100 nM control siRNA or β-catenin siRNA prior to treatment with 1 mM VPA 
for 48 h. (A) Whole-cell lysates were subjected to immunoblotting to detect presence of β-catenin, Pan-Ras, p-ERK, p21Cip/
WAF1, Tuj1, EGFR, or β-actin. (B-C) Immunofluorescent labeling of Tuj1or BrdU. Nuclei were counterstained with DAPI.BMC Cell Biology 2008, 9:66 http://www.biomedcentral.com/1471-2121/9/66
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NPCs by overcoming the effect of bFGF, a factor which
promotes growth/proliferation and suppresses differenti-
ation, through the common ERK-p21Cip/WAF1 pathway.
The VPA-induced inhibition of proliferation was sup-
pressed by the MEK inhibitor PD98059, indicating a role
for activation of the ERK pathway in the inhibition of pro-
liferation by VPA. Participation of the ERK pathway in
inhibition of proliferation is frequently accompanied by
induction of the cell cycle inhibitory factor p21Cip/WAF1
[6,31,34,35]; p21Cip/WAF1 was also induced in the VPA-
treated NPCs. The role of p21Cip/WAF1 in inhibition of pro-
liferation by VPA is also shown by release of the VPA-
induced inhibition of proliferation by p21Cip/WAF1 siRNA.
The role of p21Cip/WAF1 as a potent anti-proliferation factor
was further shown by loss of BrdU incorporation in most
cells in which p21Cip/WAF1 had been induced by VPA.
A significant decrease in the level of Tuj1 following siRNA-
mediated p21Cip/WAF1 knockdown, demonstrated by both
biochemical and immunocytochemical analyses, suggests
that p21Cip/WAF1 may also be involved in the regulation of
differentiation and inhibition of proliferation. It is clear
that both inhibition of proliferation and differentiation of
NPCs stimulated by VPA occur through the ERK pathway-
dependent induction of p21Cip/WAF1.
We have shown that activation of the ERK-p21Cip/WAF1
pathway by VPA did not occur via the segment of the path-
way involving EGFR but via the segment involving β-cat-
enin. Although EGFR has been identified as a target of
Wnt/β-catenin in liver [36], EGFR was reduced by VPA in
NPCs. The mechanism by which EGFR transcription is
inhibited by VPA is unknown; however, it has been estab-
lished that EGFR transcription is repressed by bone mor-
phogenetic protein 4 (BMP4), an alternative transcription
target of β-catenin [37], in NPCs [38,39]. We observed sig-
nificant induction of BMP4 in the VPA-treated NPCs
grown in the presence of bFGF (data not shown). These
data suggest that the VPA-induced decrease in EGFR in
NPCs may be acquired through induction of BMP4.
VPA directly inhibits GSK3β resulting in activation of the
β-catenin signaling pathway [33,40,41] and β-catenin is,
in turn, involved in regulation of the ERK pathway
Effects of VPA on differentiation and proliferation in cerebral cortex of the developing embryo Figure 6
Effects of VPA on differentiation and proliferation in cerebral cortex of the developing embryo. (A) Coronal sec-
tions of E15.5 rat embryo cerebral cortex immunofluorescently labelled for Tuj1 (green) and PCNA (red). (B) Rats at E13.5 of 
gestation were intravenously injected with 200 mg/kg VPA or PBS at 0 and 24 h and sacrificed. Immunofluorescence labeling of 
Tuj1 (green) and PCNA (red) was performed on coronal sections of embryonic brains of the E15.5 rat. The three layers of the 
cerebral cortex – the cortical plate (CP), the intermediate zone (IMZ), and the subventricular zone (SVZ) above the lateral 
ventricle (LV)- can be distinguished. The white arrow indicates the direction of migration of the differentiating cells (bar = 25 
μm). (C) NPCs from E14 embryos were incubated in the presence of 10 ng/ml bFGF in the presence or absence of 1 mM VPA 
for 48 h. Immunofluorescence labeling was performed with anti-Tuj1 and anti-BrdU. Nuclei were counterstained with DAPI.BMC Cell Biology 2008, 9:66 http://www.biomedcentral.com/1471-2121/9/66
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[21,22]. Evidence for the role of β-catenin in VPA-induced
activation of the ERK-p21Cip/WAF1 pathway, and subse-
quent effects on differentiation and inhibition of prolifer-
ation in NPCs, was seen in the reduction of the effects of
VPA, including ERK activation and induction of p21Cip/
WAF1  and Tuj1, following siRNA-mediated β-catenin
knockdown. The β-catenin-mediated activation of the
ERK-p21Cip/WAF1 pathway following VPA treatment may
be attributed to upregulation of Ras, suggested by the
increase in the level of Ras seen after β-catenin overexpres-
sion. The VPA-induced increase in the level of Ras may be
due to the stabilization of β-catenin as a result of inhibi-
tion of GSK3?. Increases in Ras following modulation of
the Wnt/β-catenin signaling pathway have been demon-
strated in various cell types, including primary hepato-
cytes, and β-catenin has been identified as an important
mediator of that process [21,22]. Regulation of Ras pro-
tein levels by the Wnt/β-catenin system is mediated by
polyubiquitination and proteasomal degradation [Kim et
al., 2008, Journal of Cell Science, In print]. Differentiation
and proliferation occur independently in the cerebellar
cortex of the developing embryo [42-44]; however, the
mechanism(s) underlying the differential regulation of
the two processes has not been described. In this study, we
found that differentiation and proliferation occurred
independently in regions of the developing brain of
embryos treated with VPA. We saw no BrdU-positive cells
among Tuj1-positive NPCs following VPA treatment. We
also did not observe any proliferating cells among differ-
entiated NPCs stimulated to differentiate by β-catenin
overexpression or by VPA treatment to express increased
levels of p21Cip/WAF1. These results indicate that mutually
exclusive patterns of differentiation and proliferation dur-
ing neuronal differentiation and development may be reg-
ulated via the common Ras-ERK-p21Cip/WAF1  pathway
involving β-catenin.
However, the effects of VPA, particularly its effect on pro-
liferation, were modest or only partially inhibited by
increases in p21Cip/WAF1  or siRNA-mediated β-catenin
knockdown in several different cases. These results indi-
cate the possibility that VPA-induced differentiation and
inhibition of proliferation occur in part via different
routes, including, e.g., the pathway affected by inhibition
of HDAC [8]. Although we improved the efficiency of
transfection by making modifications to the standard
method, the limited effectiveness of siRNAs in general
may also be a contributing factor in the weak effects seen
on differentiation and inhibition of proliferation (see
Additional file 7). The concomitant stimulation of differ-
entiation and inhibition of proliferation in NPCs and the
developing rat embryo by VPA treatment indicate poten-
tial utility for VPA in the treatment of neuroblastomas
[45] and/or in neuronal regeneration.
Conclusion
Our results suggest that VPA induces neuronal differentia-
tion and inhibition of proliferation of cortical NPCs at
least partly via the Ras-ERK-p21Cip/WAF1-pathway medi-
ated by β-catenin. We propose that this mechanism of
VPA action may contribute to an explanation of its anti-
tumor and neuroprotective effects, as well as elucidate its
role in the independent regulation of differentiation and
proliferation in the cerebral cortex of developing rat
embryos. Regulation of Ras stability in neuronal differen-
tiation and inhibition of proliferation may indicate a new
role of the protooncoprotein Ras in the differentiation of
stem cells and in development.
Methods
Primary cerebral cortical progenitor cell culture, 
transfection, and VPA treatment
Sprague-Dawley (SD) rats were purchased from KOAT-
ECH (Gyeonggi Do, Korea). All animal procedures were
approved by the Institutional Review Board of Severance
Hospital, Yonsei University College of Medicine. NPCs
were isolated from the cerebral cortex of E14 SD rats as
described previously [26]. The isolated cortical cells were
plated in dishes coated with 15 μg/ml poly-L-ornithine
and 10 μg/ml fibronectin (Sigma-Aldrich, St. Louis, MO)
and cultured in N2 medium [DMEM:F12 (1:1) (Invitro-
gen) containing 100 μM putrescine, 30 nM selenite, 20
nM progesterone, 1.55 mg/ml D-(+)-glucose, 25 μg/ml
insulin, 0.1 μg/ml apo-transferrin (Sigma-Aldrich), 0.5
mM Glutamax, 100 IU/ml penicillin, and 100 μg/ml
streptomycin] containing 10 ng/ml bFGF (basic Fibrob-
last Growth Factor; Invitrogen, Carlsbad, CA) in a humid-
ified atmosphere of 95% air/5% CO2 at 37°C. NPCs were
plated at 4 – 5 × 105 cells per dish in a 60-mm culture dish
and grown to 40% confluence, cells were treated with 0.5
– 10 mM (most often 1 mM) VPA for 48 h. To observe the
effect of inhibition of MEK, some cultures were co-treated
with 20 μM PD98059 (2'-amino-3'-methoxyflavone) (A
G. Scientific Inc, San Diego, CA) in addition to VPA. To
test the effects of overexpression or knockdown, vectors or
siRNAs were transfected into NPCs using Lipofectamine
TM 2000 (Invitrogen). Transfections were performed in
N2 medium without antibiotics, followed by growth in
N2 medium containing 50 IU/ml penicillin and 50 μg/ml
streptomycin, prior to treatment with VPA. Cultures were
photographed using the ECLIPS TE2000-U Fluorescent
microscope (Nikon, Tokyo, Japan) equipped with a dig-
ital CCD camera (Diagnostic Instruments, Inc., Sterling
Heights, MI).
VPA Treatment of embryos
Beginning on embryonic day 13.5 (E13.5) of gestation,
rats were intravenously injected with 200 mg/kg VPA
(Acros Organics, Belgium) or phosphate-buffered salineBMC Cell Biology 2008, 9:66 http://www.biomedcentral.com/1471-2121/9/66
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(PBS) twice at 24 h intervals, and provided with water
containing 15 g/l VPA for 48 h. On day15.5 embryos were
collected for subsequent immunohistochemical analyses.
Immunoblot Analysis
Cells were rinsed with ice-cold PBS and lysed in 1× Lae-
mmli buffer (0.14 M Tris, pH 6.8, containing 2.4 M glyc-
erol, 0.21 M sodium dodecyl sulfate, and 0.3 mM
bromophenol blue). Cell lysates were heated at 100°C for
10 min and separated by electrophoresis through 8 – 12%
SDS-polyacrylamide gels. Following electrophoretic trans-
fer of proteins to nitrocellulose, membranes were blocked
in 5% nonfat dry milk in PBS containing 0.1% (v/v)
Tween 20 for 30 min at 25°C followed by incubation with
anti-p-ERK, anti-p-MEK, anti-p-GSK3β (Ser-9) (Cell Sign-
aling Biotechnology, Beverly, MA), anti-β-catenin (rabbit
polyclonal antibody produced in this laboratory), anti-
p21Cip/WAF1, anti-EGFR (Santa Cruz Biotechnology, Santa
Cruz, CA), anti-p-Raf-1 (Ser-338), anti-pan-Ras (Upstate
Biotechnology, Lake Placid, NY), anti-Tuj1 (Covance,
Princeton, NJ), or anti-β-actin (Abcam Ltd, MA) antibody
followed by horseradish peroxidase-conjugated second-
ary anti-rabbit, anti-rat (Calbiochem, La Jolla, CA), or
anti-mouse IgG (Bio-Rad Laboratories, Hercules, CA).
Protein bands were visualized using enhanced chemilu-
minescence (ECL; Amersham, Inc, UK) and the LAS-3000
imaging system (Fujifilm, Tokyo, Japan).
Immunocytochemistry and Immunohistochemistry
For immunocytochemistry, NPCs were plated on cover-
slips coated with poly-L-ornithine and fibronectin in 24-
well plates at a density of 2 – 2.5 × 104 cells/well. When
cultures reached 30% confluence VPA was added to the
medium. Where indicated, the cells had been transfected
with 100 nM p21Cip/WAF1 siRNA or β-catenin siRNA for 12
h before VPA treatment. For the proliferation assay, cul-
tures were incubated with 25 μM BrdU (Sigma-Aldrich)
for 2.5 h before fixation. Cells were fixed in 70% ethanol
for 30 min, washed three times with PBS, and permeabi-
lized by incubation in 0.1% Triton X-100 in PBS for 30
min. To measure BrdU incorporation, cells were incu-
bated in 2 M HCl for 30 min and washed three times with
PBS. The cells were incubated in blocking solution (10%
normal goat serum in PBS) for 30 min followed by incu-
bation with anti-Tuj1, anti-BrdU (Dako Co., Carpinteria,
CA), anti-Flag (Sigma-Aldrich), or anti-p21Cip/WAF1  in
blocking solution at 4°C overnight. Cells were washed
three times in PBS and incubated with Alexa Fluor 488- or
Alexa Fluor 555-conjugated IgG secondary antibody
(Molecular Probes, Eugene, OR) at room temperature for
1 h. Nuclei were counterstained by incubation in 1 μg/ml
DAPI (4',6-diamidino-2-phenylindole; Boehringer Man-
nheim, Mannheim, Germany) for 10 min followed by
exhaustive washing in distilled water. Coverslips were
mounted in GelMount (Biomeda, Foster City, CA). Fluo-
rescent labeling was observed using a Radiance 2100
multi-photon imaging system (Bio-Rad Laboratories) and
LSM510META (Carl Zeiss, Germany) at excitation wave-
lengths of 488 nm (Alexa Fluor 488), 543 nm (Alexa Fluor
555), or 405 nm (DAPI). Approximately 300–400 cells
were counted in each of three independent experiments to
quantify relative p21Cip/WAF1-, Tuj1-, or BrdU- positive
cells. For histological analyses, embryos were fixed in 10%
neutral buffered formalin for 48 h, dehydrated by serial
immersion in alcohols, cleared in xylene, and embedded
in paraffin. Four-micron sections were cut using a
RM2245 microtome (Leica Microsystems Wetzlar, Ger-
many). Immunohistochemical analysis was performed
using Alexa Fluor 555- and 488-conjugated IgG secondary
antibodies. Antigen retrieval was performed using citrate
buffer, pH 6.0. All incubations were carried out in humid-
ified chambers in the dark. Immunofluorescent labeling
of tissue sections was performed using the staining proce-
dure described above.
Vector and siRNAs
Flag-β-catenin-pcDNA3.0 was obtained from Dr. Eric R.
Fearon of the University of Michigan School of Medicine.
Small interfering RNAs (siRNAs) targeting rat p21Cip/WAF1
(GenBank accession number NM_080782) and β-catenin
(GenBank accession number NM_053357) mRNAs were
designed using the template design tool (Ambion, Austin,
TX). The p21Cip/WAF1  target sequences are 5'-AGAC-
CAGCCUAACAGATTTTT-3' (431–459) and 5'-GAACG-
GTGGAACTTTGACTTT-3' (136–154).  -catenin  target
sequences are 5'-AAGGCTTTTCCCAGTCCTTCA-3' (203–
223) and 5'-AAGATGATGGTGTGCCAAGTG-3' (1303–
1323). β-catenin and p21Cip/WAF1siRNAs were synthesized
by Samchully Pharm Co., LTD (Gyeonggi do, Korea).
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